Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia.
There is evidence that the duration of untreated psychosis may affect both the course and outcome of treatment in schizophrenic patients. In the present study, we used neuroendocrine probes to test the hypothesis that untreated psychosis may induce time-dependent changes in central serotonergic and dopaminergic neurotransmission. Prolactin responses to the administration of clomipramine (i.v.) and haloperidol (i.m.) were measured in healthy control subjects and in 16 never-treated male patients with DSM-IV diagnoses of schizophreniform or schizophrenic disorders of paranoid subtype, both before and after 5 weeks of treatment with haloperidol. In the drug-free state, schizophrenic patients exhibited significantly increased prolactin responses to clomipramine administration compared with both the healthy control subjects and the schizophreniform patients. Maximum prolactin responses to clomipramine in the total group of patients were positively correlated with the duration of psychotic illness and negatively correlated with changes in Positive and Negative Syndrome Scale (PANSS) total, negative symptoms and general psychopathology scores after 5 weeks of treatment with haloperidol. Prolactin responses to haloperidol challenge in the drug-free state were lower in the schizophreniform group than in the control and the schizophrenic groups, but the differences did not reach statistical significance. The results provide evidence that the persistence of psychotic psychopathology induces secondary neuroadaptive effects, which seem to involve changes in central serotonergic function.
Angelopoulos
Elias K
EK
Athens University, Medical School, Psychiatric Clinic, Eginition Hospital, Vas. Sophias 74, Athens 115 28, Greece. eangel@ath.forthnet.gr
Markianos
Manolis
M
Daskalopoulou
Eugenia G
EG
Hatzimanolis
John
J
Tzemos
John
J
D000293:Adolescent; D000328:Adult; D001921:Brain / Q000503:physiopathology; D002908:Chronic Disease; D002997:Clomipramine; D004298:Dopamine / Q000502:physiology; D006220:Haloperidol; D006801:Humans; D008297:Male; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales; D012563:Schizophrenia, Paranoid / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D012701:Serotonin / Q000502:physiology*; D009435:Synaptic Transmission / Q000502:physiology
D012701:Serotonin; D011388:Prolactin; D006220:Haloperidol; D002997:Clomipramine; D004298:Dopamine